Literature DB >> 20888225

Discovery of a vorapaxar analog with increased aqueous solubility.

Yan Xia1, Samuel Chackalamannil, William J Greenlee, Yuguang Wang, Zhiyong Hu, Yuriko Root, Jesse Wong, Jianshe Kong, Ho-Sam Ahn, George Boykow, Yunsheng Hsieh, Stan Kurowski, Madhu Chintala.   

Abstract

An analog of the thrombin receptor antagonist vorapaxar (SCH 530348) with increased aqueous solubility, compound 9c (SCH 602539), was discovered through incorporation of polar substituents on the pyridine ring of the himbacine-derived lead series. This analog retained the excellent potency, pharmacokinetic and safety properties of vorapaxar while increasing the aqueous solubility by 20-fold. Also presented are in vivo evaluations of this compound in a cynomolgus monkey platelet aggregation assay and in a Folts model of thrombosis in anesthetized monkeys.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20888225     DOI: 10.1016/j.bmcl.2010.09.009

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar.

Authors:  Mariappan V Chelliah; Keith Eagen; Zhuyan Guo; Samuel Chackalamannil; Yan Xia; Hsingan Tsai; William J Greenlee; Ho-Sam Ahn; Stan Kurowski; George Boykow; Yunsheng Hsieh; Madhu Chintala
Journal:  ACS Med Chem Lett       Date:  2014-03-11       Impact factor: 4.345

Review 2.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

3.  Discovery of Octahydroindenes as PAR1 Antagonists.

Authors:  Sunkyung Lee; Jong-Hwan Song; Chul Min Park; Jin-Seok Kim; Ji-Hye Jeong; Woo-Young Cho; Dong-Chul Lim
Journal:  ACS Med Chem Lett       Date:  2013-09-10       Impact factor: 4.345

4.  Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar.

Authors:  Mariappan V Chelliah; Samuel Chackalamannil; Yan Xia; William J Greenlee; Ho-Sam Ahn; Stan Kurowski; George Boykow; Yunsheng Hsieh; Madhu Chintala
Journal:  ACS Med Chem Lett       Date:  2013-12-18       Impact factor: 4.345

5.  Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.

Authors:  Michael P Bokoch; Hyunil Jo; James R Valcourt; Yoga Srinivasan; Albert C Pan; Sara Capponi; Michael Grabe; Ron O Dror; David E Shaw; William F DeGrado; Shaun R Coughlin
Journal:  Biochemistry       Date:  2018-08-27       Impact factor: 3.162

Review 6.  Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar.

Authors:  Mohamed Farag; Hiten Patel; Diana A Gorog
Journal:  Drug Des Devel Ther       Date:  2015-07-22       Impact factor: 4.162

Review 7.  Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.

Authors:  Jung Rae Cho; Fabiana Rollini; Francesco Franchi; Elisabetta Ferrante; Dominick J Angiolillo
Journal:  Vasc Health Risk Manag       Date:  2014-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.